To highlight the roles of pivotal transcription factors (TFs) in myelomagenesis and multiple myeloma (MM) pathobiology.
Approach:
Introduction to Multiple Myeloma: Multiple myeloma is characterized by the proliferation of clonal plasma cells and is often preceded by MGUS and SMM. Despite treatment advances, MM remains incurable due to genetic and transcriptional heterogeneity.
Role of Transcription Factors: Transcriptional dysregulation is a hallmark of oncogenesis, with TFs playing a central role in gene expression networks that sustain myeloma cell survival and contribute to drug resistance.
Mechanisms of TF Action: TFs act as coactivators or corepressors, binding to specific DNA sequences to regulate gene expression. They can also form complexes that enhance transcriptional precision.
TFs in B-cell Development: TFs are essential in B-cell differentiation into plasma cells, guiding lineage commitment and ensuring functional maturation.
Key Findings:
TFs are implicated in the pathogenesis of multiple myeloma.
Aberrant TF activity can lead to uncontrolled proliferation and therapeutic resistance in MM.
Recent advances in therapeutic modalities have opened new opportunities for targeting TFs in MM.
Interpretation:
The review emphasizes the importance of understanding TF dysregulation in MM to identify novel therapeutic strategies.
Limitations:
The review does not provide specific clinical trial data or outcomes related to TF-targeted therapies.
Further research is needed to elucidate the mechanisms of TF dysregulation in MM.
Conclusion:
Transcription factors play a critical role in the biology of multiple myeloma.
